mCRPC in focus
Transcript: ctDNA and PSMAfore at ASCO GU 2025
Professor Silke Gillessen
Interview recorded February 2025. All transcripts are created from interview footage and directly reflect the content of the interview at the time. The content is that of the speaker and is not adjusted by Medthority.
Yeah, and the lutetium session was also very interesting. More translational abstract, abstract 16 presented by Johann de Bono. That was for samples from the PSMAfore study, and they looked at association between the baseline and on-treatment ctDNA fraction and clinical outcomes in patients of this PSMAfore study, and you remember PSMAfore is the study that tests Lu-PSMA after one line of ARPI versus another ARPI, and we have seen that data, and, like, to make it short, it was quite interesting.
A decrease in ctDNA is associated with our rPFS. There was also, of course, the prognostic factor, but in reality, for us now, as clinicians, we have a lot of prognostic factors, more important, or predictive factors, to guide our treatments. I think that was quite interesting. There was also a quite interesting discussion about, I found, you know, that is there a circadian rhythm to ctDNA? Should we always take it at the same time? And of course, that will be ideal, and interestingly, Johann de Bono said that it seems that ctDNA is specifically shredded during nighttime, and we don't know why, but that was I think, a quite interesting discussion there.
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.